Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
NKGen Biotech develops off-the-shelf and autologous natural killer (NK) cell therapies for neurodegenerative and oncological diseases. Utilizing proprietary manufacturing processes, the company produces highly active, cryopreserved NK cells designed for scalable, durable, and effective immune-based treatments. Focused on clinical development and strategic collaborations, NKGen aims to transform cellular immunotherapy with innovative, scalable solutions targeting cancer and neurodegenerative conditions.
This description was generated via AI from an annual report. Updated about 1 year ago.